Nyxoah SA announced a new manufacturing footprint in Wallonia, Belgium, adding a nearly 2,000‑square‑meter facility in Mont‑Saint‑Guibert. The plant will be built in partnership with ABN Cleanroom Technology and housed within the LégiaPark life‑sciences business park, giving the company a state‑of‑the‑art cleanroom and advanced infrastructure.
The expansion follows the U.S. Food and Drug Administration’s approval of the Genio hypoglossal neurostimulation system in August 2025, which has accelerated demand in the United States and other international markets. By increasing domestic production capacity, Nyxoah aims to reduce lead times, lower logistics costs, and strengthen its gross‑margin profile as it scales its commercial organization.
The Genio system is a battery‑free, bilateral neurostimulation therapy for moderate‑to‑severe obstructive sleep apnea. Since FDA approval, the company’s revenue grew 122 % year‑over‑year to €10 million in 2025, driven largely by U.S. commercial sales. The new facility will help Nyxoah meet this growth and avoid supply bottlenecks that could erode margins.
CEO Olivier Taelman said the investment “strengthens Nyxoah’s supply‑chain resilience and positions the company for continued U.S. expansion.” LégiaPark CEO Isabelle Degand highlighted the park’s advanced infrastructure and collaborative environment, while ABN Cleanroom CEO Jo Nelissen emphasized the cleanroom’s scalability and design for future growth.
While the investment is significant, Nyxoah expects the expanded capacity to deliver cost efficiencies and margin gains as production scales. The company’s prior gross margin of 60.5 % in Q3 2025 indicates a focus on margin preservation, and the new facility is part of that strategy.
The expansion also creates local jobs in Belgium, reinforcing Nyxoah’s partnership with the regional life‑science ecosystem and supporting the company’s long‑term growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.